These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 05.06.2020 and posted on 08.06.2020by Johannes Karges, Jia Li, Leli Zeng, Hui Chao, Gilles Gasser
therapy is a medical technique, which is gaining increasing attention
to treat various types of cancer. Among the investigated classes of
photosensitizers, the use of Ru(II) polypyridine complexes is gaining
momentum. However, the currently investigated compounds generally show
poor cancer cell selectivity. As a consequence, high drug doses are
needed, which can cause side effects. To overcome this limitation, there
is a need for the development of a suitable drug delivery system to
increase the amount of PS delivered to the tumor. Herein, we report on
the encapsulation of a promising Ru(II) polypyridyl complex into
polymeric nanoparticles with terminal biotin groups. Thanks to this
design, the particles showed much higher selectivity for cancer cells in
comparison to non-cancerous cells in a 2D monolayer and 3D
multicellular tumor spheroid model. As a highlight, upon intravenous
injection of an identical amount of the Ru(II) polypyridine complex, an improved accumulation inside an adenocarcinomic human alveolar basal epithelial tumor
of a mouse by a factor of 8.7 compared to the Ru complex itself was
determined. The nanoparticles were found to have a high phototoxic
effect upon 1-photon (500 nm) or 2-photon (800 nm) excitation with an
eradication of an adenocarcinomic human alveolar basal epithelial tumor inside a mouse. Overall, this work describes, to the best of our knowledge, the first in vivo
study demonstrating the cancer cell selectivity of a very promising
Ru(II)-based PDT photosensitizer encapsulated into polymeric
nanoparticles with terminal biotin groups.